Effects of valproate on neurotransmission associated with ryanodine receptors

Neuroscience Research

Volumn 68, Issue 4, 2010, Pages 322-328

  Yoshida, Shukuko ^a,b   Yamamura, Satoshi ^c   Ohoyama, Keiko ^c   Nakagawa, Masanori ^c   Motomura, Eishi ^c   Kaneko, Sunao ^a   Okada, Motohiro ^a,c  

^a HIROSAKI UNIVERSITY   (Japan)

^b Institute of Neuroscience and Molecular Biology   (Japan)

^c MIE UNIVERSITY   (Japan)

Author keywords

Epilepsy; GABA; Glutamate; Hippocampus; Ryanodine receptor; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; MESSENGER RNA; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 2; RYANODINE RECEPTOR 3; VALPROIC ACID;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN PERFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; HIPPOCAMPUS; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANTIMANIC AGENTS; BLOTTING, WESTERN; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SYNAPTIC TRANSMISSION; VALPROIC ACID;

EID: 78149469911     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2010.08.010     Document Type: Article

References (32)

1. Berg M., Bruhn T., Frandsen A., Schousboe A., Diemer N.H. Kainic acid-induced seizures and brain damage in the rat: role of calcium homeostasis. J. Neurosci. Res. 1995, 40:641-646.
2. Berridge M.J. Neuronal calcium signaling. Neuron 1998, 21:13-26.
3. Bolt M.W., Mahoney P.A. High-efficiency blotting of proteins of diverse sizes following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 1997, 247:185-192.
4. Bourgeois B. Valproic acid: clinical efficacy and use in epilepsy. Antiepileptic Drugs 2002, 808-817. Lippincott Williams & Wilkins, Philadelphia. 5th ed. M.B. Mattson, E. Perucca (Eds.).
5. Dong E., Agis-Balboa R.C., Simonini M.V., Grayson D.R., Costa E., Guidotti A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12578-12583.
6. Evins A.E. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J. Clin. Psychiatry 2003, 64(Suppl. 8):9-14.
7. 3H]dopa in various regions of the brain. J. Neurochem. 1966, 13:655-669.
8. Hirose S., Okada M., Kaneko S., Mitsudome A. Are some idiopathic epilepsies disorders of ion channels? A working hypothesis. Epilepsy Res. 2000, 41:191-204.
9. Hoffmann K., Czapp M., Loscher W. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?. Epilepsy Res. 2008, 81:107-113.
10. 2+ mobilization in rat hippocampus. Epilepsy Res. 1999, 35:173-182.
11. Kim S., Yun H.M., Baik J.H., Chung K.C., Nah S.Y., Rhim H. Functional interaction of neuronal Cav1.3 L-type calcium channel with ryanodine receptor type 2 in the rat hippocampus. J. Biol. Chem. 2007, 282:32877-32889.
12. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
13. McElroy S.L., Keck P.E., Pope H.G. Sodium valproate: its use in primary psychiatric disorders. J. Clin. Psychopharmacol. 1987, 7:16-24.
14. McLean M.J., Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 1986, 237:1001-1011.
15. Mori F., Okada M., Tomiyama M., Kaneko S., Wakabayashi K. Effects of ryanodine receptor activation on neurotransmitter release and neuronal cell death following kainic acid-induced status epilepticus. Epilepsy Res. 2005, 65:59-70.
16. Okada M., Yoshida S., Zhu G., Hirose S., Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 2005, 134:233-246.
17. Pal S., Limbrick D.D., Rafiq A., DeLorenzo R.J. Induction of spontaneous recurrent epileptiform discharges causes long-term changes in intracellular calcium homeostatic mechanisms. Cell Calcium 2000, 28:181-193.
18. Paschen W., Frandsen A. Endoplasmic reticulum dysfunction-a common denominator for cell injury in acute and degenerative diseases of the brain?. J. Neurochem. 2001, 79:719-725.
19. Paxinos G., Watson C. The Rat Brain: In Stereotoxic Coordinates 1998, Academic Press, San Diego.
20. Pelletier M.R., Wadia J.S., Mills L.R., Carlen P.L. Seizure-induced cell death produced by repeated tetanic stimulation in vitro: possible role of endoplasmic reticulum calcium stores. J. Neurophysiol. 1999, 81:3054-3064.
21. Pfaffl M. Relative quantification. Real Time PCR (BIOS Advanced Methods) 2006, 63-82. Taylor & Francis, New York. T. Dorak (Ed.).
22. Popescu B.O., Oprica M., Sajin M., Stanciu C.L., Bajenaru O., Predescu A., Vidulescu C., Popescu L.M. Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. J. Cell Mol. Med. 2002, 6:555-569.
23. Raza M., Blair R.E., Sombati S., Carter D.S., Deshpande L.S., DeLorenzo R.J. Evidence that injury-induced changes in hippocampal neuronal calcium dynamics during epileptogenesis cause acquired epilepsy. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17522-17527.
24. Sachs G.S. Decision tree for the treatment of bipolar disorder. J. Clin. Psychiatry 2003, 64(Suppl. 8):35-40.
25. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., Sharma R., Grayson D.R., Costa E., Guidotti A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:17095-17100.
26. Wu S.P., Tsai J.J., Gean P.W. Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br. J. Pharmacol. 1998, 125:826-832.
27. Yamamura S., Hamaguchi T., Ohoyama K., Sugiura Y., Suzuki D., Kanehara S., Nakagawa M., Motomura E., Matsumoto T., Tanii H., Shiroyama T., Okada M. Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res. 2009, 84:172-186.
28. Yamamura S., Ohoyama K., Hamaguchi T., Nakagawa M., Suzuki D., Matsumoto T., Motomura E., Tanii H., Shiroyama T., Okada M. Effects of zotepine on extracellular levels of monoamine GABA and glutamate in rat prefrontal cortex. Br. J. Pharmacol. 2009, 157:656-665.
29. Yamamura S., Ohoyama K., Nagase H., Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 2009, 57:322-331.
30. Yamamura S., Saito H., Suzuki N., Kashimoto S., Hamaguchi T., Ohoyama K., Suzuki D., Kanehara S., Nakagawa M., Shiroyama T., Okada M. Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors. Neurosci. Lett. 2009, 454:91-96.
31. Yoshida S., Okada M., Zhu G., Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res. 2005, 67:153-162.
32. Yoshida S., Okada M., Zhu G., Kaneko S. Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 2007, 52:1538-1546.